Additive Cardiorenal Benefits of Finerenone and SGLT2 Inhibitor Combination Therapy in Diabetic CKD: A Propensity-Matched Real-World Study
Finerenone and sodium-glucose cotransporter-2 inhibitors (SGLT2i) independently improve cardiovascular and renal outcomes in diabetic chronic kidney disease (CKD), but real-world evidence on their combined use is understudied. Using the TriNetX…
read more